A RANDOMIZED, DOUBLE MASKED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGE FINDING STUDY TO ASSESS THE EFFICACY AND SAFETY OF FWY003 IN PARTICIPANTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
- Registry ID
- CFWY003A12201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2026-04-10
- Last update
- 2026-02-06
Conditions
- MACULAR DEGENERATION
- GEOGRAPHIC ATROPHY
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED TRIAL OF A SINGLE LNTRAVITREAL INJECTION OF 4D-150 IN ADULTS WITH MACULAR NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION (4FRONT-1)
- A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM CONTROLLED, REFERENCE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF ONL1204 IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA) ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION (AMD)
- PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-MASKED, 2-ARM, SHAM CONTROLLED STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF ANX007 ADMINISTERED BY INTRAVITREAL INJECTION IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD)
- A PHASE 1/2, FIRST-IN-HUMAN, MULTI-ARM, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF AN ADENO-ASSOCIATED VIRUS VECTOR VV-14295 ADMINISTERED SUPRACHOROIDALLY WITH THE EVERADS INJECTOR IN ADULTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (THE VISION STUDY)
- A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUSLY ADMINISTERED POZELIMAB IN COMBINATION WITH CEMDISIRAN OR CEMDISIRAN ALONE IN PARTICIPANTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
- A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION
View on source registry